Spontaneous bone loss in RIP-iNOS transgenic mouse: A mouse model for diabetes-mediated osteopenia/osteoporosis

Mi, Qing Sheng; Yan, Sheng; Wang, Zai Zhao; Ding, Kai; Li, Changgui; Wang, Luan; Zhou, Li; Yamamoto, Yasuhiko; Yamamoto, Hiroshi; Okamoto, Hiroshi; Isales, Carlos M.

doi:10.4161/cc.8.24.10152

Cited by 4 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, mouse models of a number of diseases were investigated for their involvement in bone metabolism; for instance diabetes, particularly type 1 Diabetes (T1D), causes frequently skeletal complications including decreased bone mass, osteoporosis and increased fracture risk. Indeed, the T1D mouse model that over-express the inducible nitric oxide synthase under rat insulin promoter control (RIP-iNOS) spontaneously develop osteopenia and could represent an useful model to study and prevent osteopenia/ osteoporosis associated to diabetes [105]. Another cause of secondary osteoporosis is hyperthyroidism [106]; several mouse models with mutations in triiodothyronine (T3) receptor gene have been generated and demonstrated that T3 has an anabolic effect during growth whereas it stimulates bone resorption in adult skeleton [107].…”

Section: Transgenic and Knockout Animal Modelsmentioning

confidence: 99%

Cellular and Animal Models for the Identification of Osteoporosis Determinants Increasing Vertebral Compression Fractures Risk

Ruosi¹,

Querques²,

Granata³

et al. 2015

J Osteopor Phys Act

View full text Add to dashboard Cite

The increase in lifespan in western society has led to a consequent increase of osteoporosis substantially decreasing quality of life and increasing healthcare costs and the need for additional therapeutic strategies. Even obesity, a major health issue in industrialized countries, has recently been associated to deteriorated bone microarchitecture and increased prevalence of vertebral fractures [8]. Currently approved therapeutic options to treat osteoporosis are several and include the estrogen replacement therapy, the use of selective estrogen receptor modulators (SERMs) such as raloxifene, the bisphosphonates (e.g., alendronate, risedronate, ibandronate, and zoledronic acid), calcitonin, recombinant human parathyroid hormone (rhPTH) and its derivatives (e.g., teriparatide), the monoclonal antibody denosumab that binds the receptor activator of nuclear factor κ-B ligand (RANKL), and strontium ranelate (not approved in the United States) [9,10]. However, there are particularly challenging categories of osteoporotic patients that show an inadequate response to therapy and patients with pre-existing conditions, such as renal or gastrointestinal diseases, that may not tolerate the existing therapies [11]. Indeed, most of the drugs currently available present contraindications and even severe side effects. For example, biphosphonates, that represent often the first-choice therapy for osteoporosis, although effective in reducing bone loss and vertebral

show abstract

Section: Transgenic and Knockout Animal Modelsmentioning

confidence: 99%